medigraphic.com

2014, Number 2

<< Back Next >>

Rev Med MD 2014; 5.6 (2)

Kidney Disease Associated to Human Immunodeficiency Virus Infection

González-Gámez M, Carrillo-Pérez DL, Carrillo-Maravilla E

Language: Spanish
References: 67
Page: 127-133
PDF size: 182.13 Kb.


ABSTRACT

The incidence of opportunistic infections has decreased with highly active antiretroviral therapy (HAART). Today the most important causes of morbi-mortality in HIV infected patients are cardiovascular, hepatica and kidney diseases. Kidney disease is a frequent complication as a consequence of the infection's risk factors and the complex interaction of traditional risk factors (diabetes, systemic arterial hypertension, obesity, etc.). Acute kidney injury is very common and often associated to hypovolemic states caused by acute and opportunistic infections. Nephrotoxicity may also result from antiretroviral drugs and prophylactic therapy. The main cause of chronic kidney disease in infected patients is HIV associated nephropathy. This entity progresses quickly and most commonly affects black population. Combined antiretroviral therapy has reduced the incidence of this condition, and increases life expectancy of patients diagnosed with this illness.
The objective of this review is to give a general perspective of kidney disease in HIV infected populations, and particularly of entities related to viral infection.


REFERENCES

  1. 1.Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378-87.

  2. 2.Peraldi MN, Maslo C, Akposso K, et al. Acute renal failure in the course of HIV infection: a singleinstitution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol Dial Transplant 1999; 14:1578-85.

  3. 3.Rao TK, Friedman EA. Outcome of severe acute renal failure in patients with acquired immunodeficiency syndrome. Am J Kidney Dis 1995; 25:390-8.

  4. 4.Franceschini N, Napravnik S, Eron JJ Jr, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67:1526-31. 5.Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561-5.

  5. 6.Choi AI, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIVinfected. Kidney Int 2010; 78:478-85.

  6. 7.Wikman P, Safont P, Del Palacio M, et al. The significance of antiretroviral-associated acute kidney González-Gámez y cols. Enfermedad renal asociada a infección por VIH Revista Médica MD Volumen 6, número 2; noviembre - enero 2015 132 injury in acohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant 2013; 28:2073-81.

  7. 8.Wyatt CM, Kitch D, Gupta SK, et al. Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovirdisoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 2014; 67:36-44.

  8. 9.Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-81.

  9. 10.Sax,P et al., 48 Week Study of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF), Each in a Single Tablet Regimen (STR) with Elvitegravir, Cobicistat, and Emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for Initial HIV Treatment. Presented at ICAAC 2013; Paper H-1464d

  10. 11.Zaidan M, Lescure FX, Brochériou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol 2013; 8:930-8.

  11. 12.Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412-20. 13.Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measuremen tofio hexoland para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75:990-6.

  12. 14.Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39: S267-75.

  13. 15.Jotwani V, Li Y, Grunfeld C, et al. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012; 59:628-35. 16.Estrella MM, Parekh RS, Astor BC, et al. Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2011; 57:380-6.

  14. 17.Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26:1907-15.

  15. 18.Mocroft A, Neuhaus J, Peters L, et al. Hepatitis B and C co-infection are independent predictors of prog ressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012; 7:e40245.

  16. 19.Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIVinfected individuals. J Infect Dis 2013; 208:1240-9.

  17. 20.Peters L, Grint D, Lundgren JD, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012; 26:1917-26. 21.Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-75.

  18. 22.Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207:1359-69.

  19. 23.Scherzer R, Gandhi M, Estrella MM, et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS 2014; 28:1289-95.

  20. 24.Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006;69:2243-2250.

  21. 25.Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: A South African perspective. Kidney Int 2006 ;69:1885-1891.

  22. 26.Gardenswartz MH, Lerner CW, Seligson GR, et al. Renaldisease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984; 21:197- 204.

  23. 27.Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:429-34.

  24. 28.Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669-73. 29.Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344:1979-84. 30.Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-5.

  25. 31.Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129-37. 32.Papeta N, Kiryluk K, Patel A, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; 22:1991-6.

  26. 33.Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013; 84:834- 40.

  27. 34.Atta MG, Estrella MM, Kuperman M, et al. HIVassociated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012; 82:338-43.

  28. 35.Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11:2079-87.

  29. 36.Ross MJ, Bruggeman LA, Wilson PD, Klotman PE. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 2001; 12:2645-51.

  30. 37.Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203-13. 38.Dickie P, Felser J, Eckhaus M, et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991; 185:109-19.

  31. 39.Bruggeman LA, Dikman S, Meng C, et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100:84-92.

  32. 40.Dickie P, Roberts A, Uwiera R, et al. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 2004; 322:69-81.

  33. 41.Kajiyama W, Kopp JB, Marinos NJ, et al. Glomerulosclerosis and viral gene expression in HIVtransgenic mice: role of nef. Kidney Int 2000; 58:1148- 59.

  34. 42.Hanna Z, Kay DG, Rebai N, et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95:163-75. 43.Husain M, Gusella GL, Klotman ME, et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002; 13:1806- 15.

  35. 44.Abbott KC, Hypolite I, Welch PG, Agodoa LY. Humanimmunod eficiency virus/acquiredimmuno deficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377-83.

  36. 45.US Renal Data System (USRDS): USRDS 2004 Annual Data Report: Atlas of End-stage Renal Disease in the United States. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2004.

  37. 46.Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1- associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-6.

  38. 47.Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008; 28:478-86.

  39. 48.Williams DI, Williams DJ, Williams IG, et al. Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS. Sex Transm Infect 1998; 74:179-84.

  40. 49.Levin ML, Palella F, Shah S, et al. Hiv-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis 2001; 37:E39.

  41. 50.Lescure FX, Flateau C, Pacanowski J, et al. HIVassociated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant 2012; 27:2349-55.

  42. 51.Bigé N, Lanternier F, Viard JP, et al. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant 2012; 27:1114-21. 52.Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69:2243-50.

  43. 53.D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18:406-21.

  44. 54.Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008; 28:478-86.

  45. 55.Atta MG, Choi MJ, Longenecker JC, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005; 118:1288. 56.Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int 2012;82:840-56.

  46. 57.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/a dultandadolescentgl.pdf

  47. 58.Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIVassociated nephropathy. Nephrol Dial Transplant 2006;21:2809-2813.

  48. 59.Stöhr W, Reid A, Walker AS, et al. DART Trial Team Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther 2011;16:1011-1020.

  49. 60.Winston JA, Burns GC, Klotman PE. Treatment of HIV-associated ne phropathy. Semin Nephrol 2000;20:293-298.

  50. 61.Pope SD, Johnson MD, May DB. Pharmacotherapy for human immunodeficiency virus–associated nephropathy. Pharmacotherapy 2005;25:1761-1772.

  51. 62.Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal sur vival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996; 28:202-8.

  52. 63.Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003; 64:1462-71. 64.Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIVassociated nephropathy. J Am Soc Nephrol 1997; 8:1140-6. 65.Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000; González-Gámez y cols. Enfermedad renal asociada a infección por VIH Revista Médica MD Volumen 6, número 2; noviembre - enero 2015 133 58:1253-60

  53. 66.Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996; 101:41-8.

  54. 67.Ingulli E, Tejani A, Fikrig S, et al. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 1991; 119:710-6.

  55. 68.Trullas JC, Cofan F, Tuset M, et al: Renal transplantation in HIV infected patients: 2010 update. Kidney Int 2011; 79:825-842.

  56. 69.Laradi A, Mallet A, Beaufils H, et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France. J Am Soc Nephrol 1998; 9: 2327–2335.

  57. 70.Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis 2008; 46:1282-9.

  58. 71.Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupuslike” features: A clinicopathologic study of 14 cases. Kidney Int 2005;67:1381-1390

  59. 72.Wearne N, Swanepoel CR, Boulle A, et al. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant 2012;27:4109- 4118.

  60. 73.Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA 1990; 263:973-8.

  61. 74.Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med 1993; 94:169-74.

  62. 75.Piédrola G, Casado JL, López E, et al. Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Clin Endocrinol (Oxf) 1996; 45:97-101.

  63. 76.Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291-5.

  64. 77.Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296-301.

  65. 78.Lachaal M, Venuto RC. Nephrotoxicity and hyperkal emia inpatients with acquired im munodeficiencys yndrometreated with pentamidine. Am J Med 1989; 87:260-3.

  66. 79.Shah GM, Alvarado P, Kirschenbaum MA. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 1990; 89:380-2.

  67. 80.Gradon JD, Fricchione L, Sepkowitz D. Severe hypomagnesemia associated with pentamidine therapy. Rev Infect Dis 1991; 13:511-2.




2020     |     www.medigraphic.com